Ganaplacide/lumefantrinein new study as world faces emerging resistance to malaria treatments
News
Takeda findings may minimise haemophilia treatment side effects
Research from Takeda and Institute Krems Bioanalytics of IMC Krems and will help treat patients
Turbine boosts AI platform to deliver cancer treatments
€20m financing will focus on treatment pathways, new partnerships and team expansion
Infex begins study of pseudomonas aeruginosa candidate RESP-X
Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers
Iveric Bio receives new therapy designation for avacincaptad pegol
FDA grants status following primary endpoint data from pivotal trials treating geographic atrophy
NICE recommends Sobi’s Doptelet to treat thrombocytopenia
Primary ITP is a rare autoimmune condition characterised by high platelet destruction
Kidney Cancer UK receives commission from NICE
The charity commissioned a two-year service quality audit of over 18,000 kidney cancer patients
Association of the British Pharmaceutical Industry lays down new antibiotics mission
The challenge of resistant infections will require new antibiotics according to the ABPI
NICE recommends Pfizer’s Paxlovid on NHS
Therapy will be available on the NHS as a clinical treatment option for adults with COVID-19
Evgen to investigate new SFX-01 tablet formulation
The therapy has the potential to treat neurological and oncological conditions
Research provides hope for patients with neurodegenerative disease
Findings highlight a potential new drug candidate that may delay disease progression
Sequana announces results from study of direct sodium removal
All ten patients involved in the research effectively and rapidly eliminated persistent congestion
Norfolk and Norwich University Hospitals establishes therapy for ovarian cancer patients
Procedure is carried out following the completion of surgery to remove all visible disease
Lindis biotech presents encouraging data from bladder cancer trial
Data revealed that 100% of patients achieved a complete remission with no recurrence
Priothera reveals positive mocravimod data
Therapy is well-tolerated in allogeneic haematopoietic cell transplantation (HCT) patients
